###
中国临床研究:2018,31(9):1215-1219
本文二维码信息
码上扫一扫!
二次电切结合吉西他滨膀胱灌注化疗治疗肌层浸润性膀胱癌
(上海市第四人民医院泌尿外科,上海 200081)
Repeat transurethral resection combined with gemcitabine intravesical instillation chemotherapy in treatment of muscle-invasive bladder cancer
(Department of Urology, Shanghai Fourth People's Hospital,Shanghai 200081, China)
摘要
本文已被:浏览 779次   下载 365
投稿时间:2018-03-15   网络发布日期:2018-09-20
中文摘要: 目的 比较二次电切结合吉西他滨膀胱灌注化疗与膀胱癌根治术治疗肌层浸润性膀胱癌的临床效果及安全性。方法 回顾性分析2011年3月至2015年3月上海市第四人民医院泌尿外科收治的204例肌层浸润性膀胱癌患者的临床资料。其中85例接受膀胱癌根治术治疗(手术组),119例接受二次经尿道电切术联合吉西他滨膀胱灌注化疗(联合组),比较两组治疗效果、手术并发症及不良反应发生情况,记录治疗前后两组尿液肿瘤标志物水平的变化;统计两组术后24个月肿瘤复发率,比较其治疗不同时间生活质量综合评定表(GQOLI-74)及卡氏功能状态量表(KPS)评分的变化。结果 联合组与手术组总缓解率差异无统计学意义(49.58% vs 51.76%,P>0.05)。联合组各手术并发症发生率低于手术组,其中呼吸道感染(0.84% vs 11.76%)、切口感染(0 vs 11.76%),组间比较差异有统计学意义(P<0.01)。联合组胃肠道反应略高于手术组,其余各不良反应发生率相近,差异均无统计学意义(P>0.05)。两组术后24个月复发率相近,差异无统计学意义(16.81% vs 16.47%,P>0.05);术前,两组尿液肿瘤标志物水平比较差异无统计学意义(P>0.05),术后3个月,两组核基质蛋白22、角蛋白19可溶性片段21-1及膀胱肿瘤抗原水平较术前降低(P<0.05),但组间比较差异无统计学意义(P>0.05)。联合组术后6、12、24个月GQOLI-74评分、KPS评分均高于手术组(P<0.01)。结论 采用二次电切术联合吉西他滨膀胱灌注化疗治疗肌层浸润性膀胱癌总缓解率高,患者术后复发率低、并发症少,且可较好改善患者生活质量及体能状况。
Abstract:Objective To compare the clinical effect of the repeat transurethral resection(re-TUR) combined with intravesical instillation chemotherapy of gemcitabine versus radical resection of bladder cancer in treatment of muscle-invasive bladder cancer. Methods The clinical data of 204 patients with muscle-invasive bladder cancer treated in the Department of Urinary Surgery of the Fourth People's Hospital of Shanghai from March 2011 to March 2015 were analyzed retrospectively, in whom there were 85 patients treated with radical resection of bladder cancer (operation group) and 119 patients treated with re-TUR combined with intravesical instillation chemotherapy of gemcitabine (combined group). The curative effect, the incidence of complications and adverse reactions were compared between two groups. Changes in urine tumor marker levels were recorded before and after treatment; the tumor recurrence rates in 2 years after operation were observed; changes in the scores of Generic Quality of Life Inventory-74(GQOLI-74) and the Karnofsky Performance Scale (KPS) at different time points were compared between two groups. Results There was no significant difference in the total remission rate between two groups (48.74% vs 51.76%, P>0.05). The incidences of complication of respiratory tract infection (0.84% vs 11.76%) and incision infection (0 vs 11.76%) in combined group were significantly lower than those in operation group(all P<0.05). The incidence of gastrointestinal response in combined group was slightly higher than that in operation group, and the incidence of other adverse reactions was similar in two groups (P>0.05). There was no significant difference in recurrence rate at 24 months after operation between two groups (16.81% vs 16.47%, P>0.05). Before operation, there were no significant differences in levels of urine tumor markers between two groups(P>0.05). At 3 months after operation, the levels of nuclear matrix protein 22(NMP22), cytokeratin 19 soluble fragment 21-1(CYFR21-1) and bladder tumor antigen(BTA) significantly decreased in both groups compared with preoperative(all P<0.05), but there were no statistical differences between two groups(all P>0.05). The scores of GQOLI-74 and KPS in combined group were statistically higher than those in operation group at different time points after operation(all P<0.01). Conclusion The re-TUR combined with intravesical instillation of gemcitabine chemotherapy has a high total remission rate, low recurrence rate and few complication, which can better improve the quality of life and physical condition of patients with muscle-invasive bladder cancer.
文章编号:     中图分类号:R 737.14    文献标志码:A
基金项目:
引用文本:
顾伟平,徐耀庭,李杜渐,顾炜,许晓文,朱彦松,罗俊.二次电切结合吉西他滨膀胱灌注化疗治疗肌层浸润性膀胱癌[J].中国临床研究,2018,31(9):1215-1219.

用微信扫一扫

用微信扫一扫